Merck's

Merck & Co. and Roche Holding AG formed a collaboration to focus on the development of diagnostic tests to help identify and monitor patients who may benefit from Merck's investigational cancer treatments.

Merck, Roche Focus on Tests for Cancer Treatments Tess Stynes 2011

About 12% of people taking Merck's simvastatin, or 1.2 million people, are taking the 80-milligram dose.

Simvastatin can damage muscles in high doses 2011

Merck's Dr. Kuter says serious problems are "very rare" and it is often unclear if they were caused by the vaccine.

Shot or Party? Avoiding Chicken Pox's Worst Laura Johannes 2011

Merck's 2007 settlement of the product-liability cases included no admission of wrongdoing.

Merck to Pay $950 Million in Vioxx Settlement Peter Loftus 2011

That position is consistent with Merck's position throughout the product-liability litigation: The company never admitted liability in lawsuits alleging Vioxx caused heart attacks and strokes, and that Merck failed to properly warn of these risks.

Merck to Pay $950 Million in Vioxx Settlement Peter Loftus 2011

Excluding special items in both periods, Merck's earnings would have risen to 97 cents a share from 88 cents a share a year earlier.

Merck Swings to Profit on Fewer Charges, Sales Growth Peter Loftus 2012

Sales of Merck's new drug for hepatitis C, Victrelis, were $87 million for the fourth quarter.

Merck Swings to Profit on Fewer Charges, Sales Growth Peter Loftus 2012

Merck's animal-health sales rose 6% to $868 million, while consumer-care sales dropped 5% to $361 million.

Merck Swings to Profit on Fewer Charges, Sales Growth Peter Loftus 2012

The Varivax vaccine, sold by Merck & Co ., consists of a weakened form of the live virus, says Barbara Kuter , executive director of medical affairs and policy for Merck's vaccine unit.

Shot or Party? Avoiding Chicken Pox's Worst Laura Johannes 2011

Merck spokesman Ronald Rogers said some sales representatives promoted Vioxx to treat rheumatoid arthritis before FDA approval, and said Merck's planned guilty plea to a violation of the Food, Drug and Cosmetic Act would be the first such plea in the company's history.

Merck to Pay $950 Million in Vioxx Settlement Peter Loftus 2011